Breath Diagnostics has developed a groundbreaking technology known as OneBreath™, which is designed to detect lung cancer through the analysis of organic compounds in a patient's breath. This patented system allows for the collection of a single breath sample in under 30 seconds, utilizing a unique collection method. The OneBreath™ micro-reactor captures and quantitatively analyzes these organic compounds, providing results within 3-4 business days. This innovative approach aims to offer a safer, more convenient, and cost-effective alternative to traditional lung cancer screening methods, such as low-dose CT scans, which often have higher false positive rates and can lead to unnecessary follow-up procedures.

The OneBreath™ technology not only enhances accessibility to lung cancer screenings by being portable enough for use in various medical settings, including physician offices and pharmacies, but it also emphasizes early detection, which is crucial for successful treatment outcomes. By focusing on the identification of specific molecular markers in exhaled breath, Breath Diagnostics aims to improve screening compliance and ultimately save lives by diagnosing lung cancer in at-risk patients before symptoms arise. This innovative platform represents a significant advancement in the field of non-invasive diagnostics, with the potential to transform lung cancer detection and management.

United States

We have developed a patented technology that will determine if a patient has lung cancer by analyzing a patient's breath with parts per billion accuracy, allowing very early detection. 

We have studied over 800 patients. This has the potential to save a significant number of lives and save the healthcare industry significant dollars.

Breath Diagnostics

Company Details